BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38380957)

  • 1. FTO promotes the progression of retinoblastoma through YTHDF2-dependent N6-methyladenosine modification in E2F3.
    Xie W; Shao Y; Bo Q; Li Z; Yu Q; Wang L; Wu G
    Mol Carcinog; 2024 May; 63(5):926-937. PubMed ID: 38380957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
    Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
    Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circ-E2F3 acts as a ceRNA for miR-204-5p to promote proliferation, metastasis and apoptosis inhibition in retinoblastoma by regulating ROCK1 expression.
    Huang Y; Xue B; Pan J; Shen N
    Exp Mol Pathol; 2021 Jun; 120():104637. PubMed ID: 33844975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA CASC9 promotes the progression of retinoblastoma via interacting with miR-145-5p.
    Zhang T; Yang J; Gong F; Li L; Li A
    Cell Cycle; 2020 Sep; 19(18):2270-2280. PubMed ID: 32772636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circular RNA (circ-0075804) promotes the proliferation of retinoblastoma via combining heterogeneous nuclear ribonucleoprotein K (HNRNPK) to improve the stability of E2F transcription factor 3 E2F3.
    Zhao W; Wang S; Qin T; Wang W
    J Cell Biochem; 2020 Jul; 121(7):3516-3525. PubMed ID: 32065448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTO regulates adipogenesis by controlling cell cycle progression via m
    Wu R; Liu Y; Yao Y; Zhao Y; Bi Z; Jiang Q; Liu Q; Cai M; Wang F; Wang Y; Wang X
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Oct; 1863(10):1323-1330. PubMed ID: 30305247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FTO promotes gastric cancer progression by modulating MAP4K4 expression via demethylation in an m6A-dependent manner.
    Yin Z; Guo X; Liang X; Wang Z
    Med Oncol; 2024 Apr; 41(5):120. PubMed ID: 38643333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FTO facilitates cancer metastasis by modifying the m
    Gao L; Wang A; Chen Y; Cai X; Li Y; Zhao J; Zhang Y; Zhang W; Zhu J; Zeng Y; Liu Z; Huang JA
    Cell Commun Signal; 2023 Nov; 21(1):311. PubMed ID: 37919739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway.
    Zhang L; Wan Y; Zhang Z; Jiang Y; Lang J; Cheng W; Zhu L
    RNA Biol; 2021 Sep; 18(9):1265-1278. PubMed ID: 33103587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m
    Tan Z; Shi S; Xu J; Liu X; Lei Y; Zhang B; Hua J; Meng Q; Wang W; Yu X; Liang C
    Oncogene; 2022 May; 41(20):2860-2872. PubMed ID: 35422475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fat mass and obesity associated (FTO)-mediated N6-methyladenosine modification of Krüppel-like factor 3 (KLF3) promotes osteosarcoma progression.
    Shan HJ; Gu WX; Duan G; Chen HL
    Bioengineered; 2022 Apr; 13(4):8038-8050. PubMed ID: 35311620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FTO up-regulation induced by MYC suppresses tumour progression in Epstein-Barr virus-associated gastric cancer.
    Xu YY; Li T; Shen A; Bao XQ; Lin JF; Guo LZ; Meng Q; Ruan DY; Zhang QH; Zuo ZX; Zeng ZL
    Clin Transl Med; 2023 Dec; 13(12):e1505. PubMed ID: 38082402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2.
    Wang F; Hu Y; Wang H; Hu P; Xiong H; Zeng Z; Han S; Wang D; Wang J; Zhao Y; Huang Y; Zhuo W; Lv G; Zhao G
    J Exp Clin Cancer Res; 2023 Oct; 42(1):267. PubMed ID: 37840133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tumor-suppressive effects of alpha-ketoglutarate-dependent dioxygenase FTO via N6-methyladenosine RNA methylation on bladder cancer patients.
    Yi W; Yu Y; Li Y; Yang J; Gao S; Xu L
    Bioengineered; 2021 Dec; 12(1):5323-5333. PubMed ID: 34499008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner.
    Huang J; Sun W; Wang Z; Lv C; Zhang T; Zhang D; Dong W; Shao L; He L; Ji X; Zhang P; Zhang H
    J Exp Clin Cancer Res; 2022 Jan; 41(1):42. PubMed ID: 35090515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRKAA1, stabilized by FTO in an m6A-YTHDF2-dependent manner, promotes cell proliferation and glycolysis of gastric cancer by regulating the redox balance.
    Zhang Y; Zhou X; Cheng X; Hong X; Jiang X; Jing G; Chen K; Li Y
    Neoplasma; 2022 Dec; 69(6):1338-1348. PubMed ID: 36305690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA N6-methyladenosine demethylase FTO promotes osteoporosis through demethylating Runx2 mRNA and inhibiting osteogenic differentiation.
    Wang J; Fu Q; Yang J; Liu JL; Hou SM; Huang X; Cao JS; Liu TL; Wang KZ
    Aging (Albany NY); 2021 Sep; 13(17):21134-21141. PubMed ID: 34496349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells.
    Mo W; Chen Z; Zhang X; Dai G; Ma D; Pan J; Zhang X; Wu G; Fan W
    Arterioscler Thromb Vasc Biol; 2022 May; 42(5):644-658. PubMed ID: 35296150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. m
    Wang X; Wu R; Liu Y; Zhao Y; Bi Z; Yao Y; Liu Q; Shi H; Wang F; Wang Y
    Autophagy; 2020 Jul; 16(7):1221-1235. PubMed ID: 31451060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTO Prevents Thyroid Cancer Progression by SLC7A11 m6A Methylation in a Ferroptosis-Dependent Manner.
    Ji FH; Fu XH; Li GQ; He Q; Qiu XG
    Front Endocrinol (Lausanne); 2022; 13():857765. PubMed ID: 35721711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.